Latest News
Press background on Morepen Laboratories
Company profile
Some things will always remain unfettered. Like sunshine and air, like suffering and joy, like sharing and caring. Some things will never recognize the confines of space and time. Like human endeavour and enterprise, like the desire to touch life. At Morepen, we are taking our expertise and experience in Wellness to new countries and new people with an increasing focus on global exports. And in doing so, our spirit of caring is crossing boundaries.
 Recent press releases
Morepen Labs' Performance Catches Pace in Q2'FY2020-21 with a Six-fold Rise in its Net Profit Led by Strong API Business

 
​Highlights: Q2’FY2020-21 (Consolidated)
 
Net Profit After Tax for Q2’FY2020-21 has grown sharply by 566 percent at Rs. 27.17 crore while Net Profit Before Tax jumped up by 198 percent on account of better margin realization during t... (more)
Share
Morepen Labs' Net Profit Rises by 153 Per cent Led by Strong API Business in Q1'FY 2020-21

 
Highlights: Q1’fy 2020-21 (Consolidated)
 
Performance at a Glance                              &nb... (more)
Share
Morepen Labs Clocks Double Digit Growth in its Sales and Net Profit in FY 2019-20

Morepen Laboratories Ltd. has reported a 16.43 per cent rise in its Net Profit (Consolidated) at Rs. 33.58 crore. Net Consolidated Revenue during the year rose by 11.7 per cent at Rs. 862.55 crore. The company’s net profit was Rs. 28.84 crore on a net revenue of Rs. 772.21 crore ... (more)
Share
Morepen Laboratories Gets ISO-13485 Certification for its Medical Devices Manufacturing Facility at Baddi (HP)

Morepen Laboratories Ltd. has received the prestigious ISO-13485 certification from BSI (British Standards Institution, U.K.) for its State-of-the-art medical devices manufacturing facility at Baddi (Himachal Pradesh). The certification has been awarded for the manufacturing, distribution a... (more)
Share
Morepen Labs takes up the COVID Battle with its Infrared Thermometers, Hand Sanitizers and Face Masks in Indian Market

Morepen Laboratories Ltd. is all set to be a frontrunner in India’s fight against Novel Coronavirus Disease (popularly referred to as COVID-19). The company has launched a wide range of essential products being required to combat the growing menace of COVID-19 and to prevent further s... (more)
Share
Morepen Labs’ Net Profit Rises by 21% in Q3' FY 2019-20 Led by a Stable Performance in All Business Segments

 
Highlights of Q3' FY 2019-20 (Consolidated)
The Net Profit after Tax during the period stood at Rs. 10.81 crore, up by 21.3 per cent from Rs. 8.91 crore net profit registered in the corresponding period of FY’2018-19.
Net Sales Revenue recorded a... (more)
Share
Morepen Labs Reports 24% Rise in its Net Sales and 34% Rise in Net Profit in First Half of FY 2019-20 Led by a Significant Jump in its Bulk Drugs and Home Diagnostics Businesses

 
Highlights of First Half (H1) FY 2019-20 (Standalone)
Net Sales Revenue recorded a growth of 24.2 per cent at Rs. 383.30 crore in H1 FY 2019-20 as compared to Rs. 308.56 crore in the corresponding first half of the previous fiscal.
EBIDTA was up by 31.... (more)
Share
Morepen Labs Adds three New Drugs - Rivaroxaban, Vildagliptin and UDCA to its API Portfolio

Three new Drugs viz., Rivaroxaban (Cardiac Segment), Vildagliptin (Diabetes segment) and UDCA (for Liver ailments) added to API portfolio.
Commercial launch of all the three drugs announced by the company, supplies to commence soon.
Global market size of Rivaroxaban... (more)
Share
Morepen Labs Catches Pharma Sector Uptrend in Q1 FY 2019-20. Company’s Net Profit Rises by a Whopping 256 Percent Led by a Significant Jump in its APIs Exports

Highlights Q1 FY 2019-20 (Standalone):
 
Net Sales Revenue recorded a pure organic growth of 25.4 per cent at Rs. 186.70 crore in Q1’FY 2019-20 as compared to Rs. 148.83 crore in the corresponding quarter of the previous fiscal
 
Net ... (more)
Share
Morepen Labs Profit Rises by 125 Percent in Q4 FY 2018-19 Led by Good Growth in All Business Segments

 
Highlights Q4 FY 2018-19
Total Revenue (Standalone) up by 31 percent at Rs. 207.10 crore and Consolidated Total Revenue up by 28 percent at Rs. 219.74 crore registering a good growth in all business segments.
Standalone Net Profit (PAT) is up by 125 pe... (more)
Share